Navigation Links
KBI Biopharma Selects Freeslate’s Biologics Formulation System for Early and Late Stage Drug Development
Date:9/3/2013

SUNNYVALE, Calif. (PRWEB) September 03, 2013

Freeslate, Inc., the leading provider of high throughput research solutions, today announced that KBI Biopharma, Inc. (KBI), a leading development and contract manufacturing organization serving the biopharmaceutical industry, has purchased Freeslate’s Biologics Formulation System to help develop more robust formulations using less time and material. The Biologics Formulation System is based on Freeslate’s Core Module 3 (CM3) automation platform and provides a new, high throughput research approach to address challenges in biologics formulation.

“The KBI team is excited to begin using Freeslate’s Biologics Formulation System to support our biologics formulation screening during early-stage development, as well as formulation robustness studies and process optimization during later stage development”, said Joseph McMahon, President and CEO for KBI. “We selected Freeslate’s technology because the system was designed for biologics formulation, combining key capabilities that can be used across both early and late stage development projects allowing us to screen a broader range of conditions and reduce product consumption while accelerating our clients’ development timelines.”

“At Freeslate, we are dedicated to advancing biologics formulation with integrated, automated solutions that address the complex problems of drug development,” said John S. Senaldi, President and CEO of Freeslate. “We have built strong capabilities in this area and are pleased to partner with KBI to continue those advances and support the important research they are doing on behalf of their clients.”

Freeslate’s Biologics Formulation System supports the entire formulation development process through the combination of automated sample prep and new high throughput capabilities for pH measurement, viscosity measurement, and visual inspection/particle counting. The system also integrates with critical analytics like Dynamic Light Scattering, High Pressure Liquid Chromatography, and UV/VIS plate readers. It enables users to develop more candidates, with more robust formulations, in a shorter period of time, with less material, with no increase in personnel. By both generating and managing data from orthogonal analytics, the system helps drive informed decision making.

KBI will serve as a reference site for Freeslate, hosting customers, product demonstrations, and participating in speaking engagements and seminars to help educate others on the available high throughput research tools. The two companies will also collaborate on future product development.

About Freeslate

Freeslate is a privately held company that provides products and related services for high throughput research. Based on its proprietary laboratory automation platforms, high throughput pressure reactors, and integrated Lab Execution and Analysis (LEA) software suite, the company enables dramatic gains in its customers’ productivity and innovation by delivering seamlessly integrated automation solutions. Freeslate leverages its scientific expertise through its team of Ph.D. scientists, engineers, and software developers with directly relevant experience in the industries it serves. Collaborating with customers for more than a decade, the business has provided high throughput research solutions for the pharmaceutical, chemical, and energy industries. The company is headquartered in Sunnyvale, California, with direct sales and service in North America, Europe, and Asia. For more information, visit http://www.freeslate.com.

About KBI

KBI Biopharma, Inc. is a leading development and contract manufacturing organization serving the biopharmaceutical industry. KBI helps client partners accelerate and optimize drug development and manufacturing programs by offering an extensive suite of expert development and manufacturing services in an agile, client-friendly partnering environment. Clients include global pharmaceutical and biotechnology companies and academic/non-profit organizations. Today, KBI serves more than 150 customers in the US, Canada, Europe, Korea and Japan, including most of the top ten pharmaceutical companies. KBI was founded in 1996 and is based in Durham, North Carolina, near Research Triangle Park (RTP).

KBI’s extensive track record of successful process development and manufacturing programs is a result of its unique approach of applying the insight gained from our biophysical and biochemical protein characterization methodologies, towards the development of robust and scalable processes. KBI delivers expert and integrated process development and cGMP manufacturing of recombinant protein Active Pharmaceutical Ingredients (API) for its clients. For more information, please visit http://www.kbibiopharma.com.

Media Contact:
Mikelle Thatcher
Marketing Communications Specialist
Freeslate, Inc.
Direct: 408-773-4081
Email: mikelle(dot)thatcher(at)freeslate(dot)com

KBI Biopharma Technical Inquiries:
Tim Kelly, Ph.D.
VP Biopharmaceutical Development
KBI Biopharma, Inc.
Phone: (919) 479-9898 ext 2045
Email: tkelly(at)kbibiopharma(dot)com

Read the full story at http://www.prweb.com/releases/2013/9/prweb11080598.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. PDL BioPharma Announces Adjusted Conversion Rates for Its Convertible Notes
3. CeNeRx BioPharma Completes $4.85 Million Financing
4. PDL BioPharma Completes Regular Quarterly Dividend Payment
5. PAREXEL Introduces Executive Briefing Series on Proven Practices to Assist Emerging and Mid-size Biopharma in Achieving Better Outcomes
6. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
7. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
8. HealthCare Institute of New Jersey Releases 2011 Biopharmaceutical and Medical Technology Economic Impact Data
9. Sigma-Aldrich to Acquire BioReliance; Extending Its Reach into Biopharmaceutical Testing and Services
10. Galien Foundation Announces 2012 Awards Program For Best Biopharmaceutical Products and Best Medical Technology
11. Laureate Biopharma Appoints Les Mintzmyer, Vice President, Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... RPS ... clinical study that demonstrates the accuracy of the FebriDx® test, a commercially-ready, ... acute bacterial and viral respiratory tract infections by testing the body’s immune ...
(Date:10/11/2017)... ... October 11, 2017 , ... At its national board ... Suneel I. Sheikh, the co-founder, CEO and chief research scientist of Minnesota-based Advanced ... for membership in ARCS Alumni Hall of Fame . ASTER Labs is ...
(Date:10/11/2017)... Md. (PRWEB) , ... October 11, 2017 , ... ... digital pathology, announced today it will be hosting a Webinar titled, “Pathology is ... Advanced Pathology Associates , on digital pathology adoption best practices and how Proscia ...
(Date:10/11/2017)... ... October 11, 2017 , ... A ... pregnancy rates in frozen and fresh in vitro fertilization (IVF) transfer ... age to IVF success. , After comparing the results from the fresh and ...
Breaking Biology Technology:
(Date:4/5/2017)... 4, 2017 KEY FINDINGS The ... at a CAGR of 25.76% during the forecast period ... primary factor for the growth of the stem cell ... MARKET INSIGHTS The global stem cell market ... and geography. The stem cell market of the product ...
(Date:3/30/2017)... YORK , March 30, 2017 Trends, ... type (physiological and behavioral), by technology (fingerprint, AFIS, iris ... voice recognition, and others), by end use industry (government ... and immigration, financial and banking, and others), and by ... Europe , Asia Pacific , ...
(Date:3/24/2017)... 24, 2017 Research and Markets has announced ... Analysis & Trends - Industry Forecast to 2025" report to ... The ... a CAGR of around 15.1% over the next decade to reach ... analyzes the market estimates and forecasts for all the given segments ...
Breaking Biology News(10 mins):